Patient-Derived Xenograft/PDX Model Market by Type, Tumor Type, Application, End-User

Description

List of Tables

[197 Pages Report] The Patient-Derived Xenograft/PDX Model Market size was estimated at USD 222.26 million in 2023 and expected to reach USD 253.51 million in 2024, at a CAGR 14.54% to reach USD 574.99 million by 2030.

A Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.

KEY MARKET STATISTICS
Base Year [2023]	USD 222.26 million
Estimated Year [2024]	USD 253.51 million
Forecast Year [2030]	USD 574.99 million
CAGR (%)	14.54%

Type: Extensive use of mouse models in oncology to develop novel therapeutics

Mice models are the most widely used PDX models due to their properties such as small size, ease of handling, and genetic similarity to humans. These models contribute significantly to understanding tumor biology and developing novel therapeutic approaches in oncology. On the other hand, rat models have emerged as a valuable alternative to mice PDX models due to their larger size, which benefits surgical procedures, imaging, and sampling. Additionally, rats exhibit more diverse immune responses and higher fidelity in modeling certain human cancer types, such as glioma and sarcoma.

Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers

Gastrointestinal (GI) tumor models are crucial to studying cancers that affect the digestive system, such as colorectal, gastric, and pancreatic cancer. These models aid in examining the underlying mechanisms of tumor development and metastasis and evaluating potential therapeutic options. Gynecological tumor models are essential for studying gynecological cancers, including ovarian, endometrial, and cervical cancer. Researchers employ hematological tumor models to study blood cancers, including leukemia, lymphoma, and multiple myeloma. Respiratory tumor models are vital for investigating lung cancer pathogenesis and treatment options. Urological tumor models, crucial for studying cancers of the urinary system such as bladder, kidney, and prostate cancer, aid researchers in comprehending disease development and identifying personalized treatment strategies.

Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research

Patient-derived xenograft (PDX) models are highly valuable in basic cancer research as they closely mimic the tumor environment and patient heterogeneity. Biomarker analysis is essential for identifying predictive or prognostic markers that guide treatment decisions for individual patients. PDX models enable comprehensive biomarker development by capturing molecular changes during tumor growth and therapy response. Preclinical drug development relies heavily on PDX models to assess investigational therapies' safety, efficacy, and pharmacokinetic properties. They are a preferred choice for evaluating anticancer agents before entering clinical trials, as PDX models replicate the complexity and diversity of human cancers.

End-User: Rising applicability of patient-derived xenografts in academic and research institutes

Academic and research institutions primarily facilitate the study of cancer biology, drug efficacy testing, and personalized medicine development. These institutions use PDX models to identify novel therapeutic targets and understand tumor progression mechanisms. Contract Research Organizations (CROs) offer preclinical and clinical trial services for pharmaceutical and biotechnology companies using PDX models for drug discovery and development. CROs apply these models in various stages of drug development, including target identification/validation, lead optimization, pharmacokinetics/pharmacodynamics (PK/PD) studies, and toxicity evaluation. Pharmaceutical and biotechnology companies employ PDX models to support their drug discovery pipelines and address the demand for personalized oncology treatments.

Regional Insights

The patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region's investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Patient-Derived Xenograft/PDX Model Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., Bioduro-Sundia, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience, Envigo RMS, LLC, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera Biolabs, Hera BioLabs Inc., Inotiv, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Merck KGaA, Oncodesign Services, Pharmatest Services Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, Vertiv Group Corp., WuXi AppTec Co., Ltd., and XENTECH.

Market Segmentation & Coverage

This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Mice Models
- Rat Models

Tumor Type
- Gastrointestinal Tumor Models
- Gynecological Tumor Models
- Hematological Tumor Models
- Respiratory Tumor Models
- Urological Tumor Models

Application
- Basic Cancer Research
- Biomarker Analysis
- Preclinical Drug Development

End-User
- Academic & Research Institutions
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Patient-Derived Xenograft/PDX Model Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Patient-Derived Xenograft/PDX Model Market?

3. What are the technology trends and regulatory frameworks in the Patient-Derived Xenograft/PDX Model Market?

4. What is the market share of the leading vendors in the Patient-Derived Xenograft/PDX Model Market?

5. Which modes and strategic moves are suitable for entering the Patient-Derived Xenograft/PDX Model Market?

Product Code: MRR-FF1601152744

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing demand for personalized medicine
  - 5.1.1.2. Oncology and preclinical development
  - 5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
- 5.1.2. Restraints
  - 5.1.2.1. High cost of personalized PDX model
- 5.1.3. Opportunities
  - 5.1.3.1. Rising demand for humanized PDX Model
  - 5.1.3.2. Growth in pharma R&D
- 5.1.4. Challenges
  - 5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
5.2. Market Segmentation Analysis
- 5.2.1. Type: Extensive use of mouse models in oncology to develop novel therapeutics
- 5.2.2. Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
- 5.2.3. Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
- 5.2.4. End-User: Rising applicability of patient-derived xenografts in academic and research institutes
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Patient-Derived Xenograft/PDX Model Market, by Type

6.1. Introduction
6.2. Mice Models
6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

7.1. Introduction
7.2. Gastrointestinal Tumor Models
7.3. Gynecological Tumor Models
7.4. Hematological Tumor Models
7.5. Respiratory Tumor Models
7.6. Urological Tumor Models

8. Patient-Derived Xenograft/PDX Model Market, by Application

8.1. Introduction
8.2. Basic Cancer Research
8.3. Biomarker Analysis
8.4. Preclinical Drug Development

9. Patient-Derived Xenograft/PDX Model Market, by End-User

9.1. Introduction
9.2. Academic & Research Institutions
9.3. Contract Research Organizations
9.4. Pharmaceutical & Biotechnology Companies

10. Americas Patient-Derived Xenograft/PDX Model Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec's 3D Spheroid Screening Platform, Kiya-Predict
- 13.3.2. Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
- 13.3.3. GemPharmatech and Charles River Laboratories Sign Exclusive Agreement to Distribute Next Generation NCG Portfolio
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio